Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyro...
Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
About this item
Full title
Author / Creator
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Cabozantinib (XL184) is an oral multiple receptor tyrosine kinase inhibitor manufactured by Exelixis Inc., CA, USA. It mainly inhibits three tyrosine kinase receptors: MET, VEGFR2 and RET. In both preclinical and clinical studies it has been shown to inhibit tumor angiogenesis, invasiveness and metastases. The most frequent side effects are fatigue...
Alternative Titles
Full title
Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1417532832
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1417532832
Other Identifiers
ISSN
1479-6694
E-ISSN
1744-8301
DOI
10.2217/fon.13.128
